Supported Symposia & Product Theaters

Symposia and Product Theater Schedule

Supported Symposia

Product Theaters

Sunday, July 9 Symposia from 14:15-15:45

Engaging in New Options for Anticoagulation Therapy
Room: A1, City Cube
Supported by an unrestricted grant from Daiichi-Sankyo Europe GmbH

Thrombotic Microangiopathies: Challenging Diseases, Challenging Stories
Room: A2, City Cube
Alexion Pharmaceuticals

DOACs and Reversal Agents: Take the Next Step in Anticoagulation Care
Room: A3, City Cube
Boehringer Ingelheim

VTE: Pervasive, Persistent, Preventable
The Unmet Need in Acutely Ill Medical Patients After Hospital Discharge
Invitation Code: ZXE6HL
Room: A5, City Cube

Innovating for Improved Outcomes: Driving the Evolution of Hemophilia A Management
Room: A7, City Cube
Bayer

SIPPET Study: One Year Later. New Insights to Help Manage “my Next Patient”
Room: A8, City Cube

Sunday, July 9 Symposia from 16:15-17:45

Haemostatic Control of aPCC: Update on the MOA, Efficacy and Safety
Room: A1, City Cube
Shire Pharmaceuticals Inc.

Controversies in Cancer and Thrombosis: Management of High-Risk Patients
Room: A2, City Cube

Management of bleeding in anticoagulated patients
Room: A3, City Cube
CSL Behring

Stopping the VTE Epidemic in Hospitalized Medically ill Patients: An Innovative, Cutting Edge and State-Of-The-Art Action Plan
Room: A5, City Cube
Medscape Education & NATF

Breaking Scientific Walls in the Treatment of Haemophilia and Rare Bleeding Disorders: From Laboratory Assays to Patient Outcomes
Room: A6, City Cube
Novo Nordisk Health Care AG

The Challenge of Cancer Associated Thrombosis (CAT): Are NOACs an Option?
Room: A7, City Cube
Bayer

Towards Life Without Limitation: Growing Experience with Nuwiq® in Patients with Haemophilia A
Room: A8, City Cube

Monday, July 10 Product Theaters from 12:15-13:00

Kovaltry in Practice: Insights From Real-World Experience
Room: Exhibition/Poster Hall 2.2

The Patient Experience in Haemophilia A: Half-Life is Not Even Half the Story
Room: Exhibition/Poster Hall 4.2
CSL Behring

4 Patients - 4 Solutions
SVT - HIT - GFR - CAT
Aspen Parenteral Anticoagulants
Room: Exhibition/Poster Hall 6.2

Monday, July 10 Symposia from 13:15-14:30

Beyond Factor: Potential New Approaches to Hemophilia
Room: Berlin, Building 7
Alnylam Pharmaceuticals

Individualising Treatment and Redefining Physical Activity to Optimise Joint Health
Room: Budapest, Building 7

Haemostasis in Critical Care Medicine
Room: Helsinki 1, Building 7
Stago

rpFVIII in Acquired Haemophilia A: Real-World Experience
Room: Helsinki 2, Building 7
Shire Pharmaceuticals Inc.

Fc Extended Half-Life Recombinant Factor Concentrates: Recent Updates on Haemophilia Management and Treatment Goals
Room: London, Building 7
Sobi Bioverativ

Managing Extended Anticoagulation Therapy in Venous Thromboembolism. What Have We Learned From EINSTEIN CHOICE?
Room: New York, Building 7
Bayer

wilate® for a Lifetime of Care: Bleeding Management Across High-Risk Patient Populations
Room: Paris, Building 7

Tuesday, July 11 Product Theaters from 12:15-13:00

NOACs in Venous Thromboembolism: Learnings from the Real World
Room: Exhibition/Poster Hall 2.2
Bayer

ST Genesia®: Thrombin Generation Entering the Clinical Lab
Room: Exhibition/Poster Hall 6.2
Stago

Tuesday, July 11 Symposia from 13:15-14:30

Extended Half-Life rFVIII: Advanced Therapeutic Options Providing Benefits in Clinical Practice
Room: Berlin, Building 7
Shire Pharmaceuticals Inc.

Reach High in Haemophilia A: Treatment With AFSTYLA
Room: Budapest, Building 7
CSL Behring

Anticoagulation and Reversal: Clinical Cases to Test your Knowledge
Room: Helsinki 1, Building 7

Immune Tolerance Induction (ITI) What Have We Learned in the Past 40 Years?
Room: Helsinki 2, Building 7

Venous Thromboembolism – Improving Patient Care With non VKA Oral Anticoagulants
Room: London, Building 7

Gene Therapy: A New Treatment Paradigm
Room: New York, Building 7
Biomarin Pharmaceutical Inc.

Treating Thrombosis Today: From Latest Data to Clinical Application
Room: Paris, Building 7

Wednesday, July 12 Product Theaters from 12:15-13:00

Integrating the Only Specific Replacement Therapy for Factor X Deficiency Into Clinical Practice
Room: Exhibition/Poster Hall 2.2
Bio Products Laboratory Ltd.

Tough Decisions in the Treatment of VTE: A Multidisciplinary Case-Based Discussion
Room: Exhibition/Poster Hall 4.2

Haemophilia Academy at 10 Years: A Platform for Career Development and Global Networking
Room: Exhibition/Poster Hall 6.2
Sponsored by an unrestricted educational grant from Novo Nordisk Health Care AG

Wednesday, July 12 Symposia from 13:15-14:30

Towards a New Era in Haemophilia Care
Room: Budapest, Building 7
This symposium is sponsored by funding from Pfizer

Management of Direct Oral Anticoagulants — Challenges and Perspectives
Room: Helsinki 1, Building 7
Doasense GmbH, Heidelberg, Germany

The Continuing Challenge of Venous Thromboembolism: Insights From the GARFIELD-VTE Registry
Room: Helsinki 2, Building 7
The GARFIELD-VTE registry is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).

Living With Haemophilia A: Raising the Bar for New Treatments
Room: New York, Building 7
Roche-Chugai

IDELVION: A Gold Standard in the Treatment of Haemophilia B?
Room: Paris, Building 7
CSL Behring